Clinical Trial News and Research

RSS
Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

NCC of South Korea, Velos agree to expand use of Velos eResearch for cancer research

NCC of South Korea, Velos agree to expand use of Velos eResearch for cancer research

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

New portable system can produce life-saving NO from air by means of electrical spark

New portable system can produce life-saving NO from air by means of electrical spark

Study could provide paradigm shift in treatment of age-related disease, cancer

Study could provide paradigm shift in treatment of age-related disease, cancer

Transitioning Infrared Imaging into Clinical Use

Transitioning Infrared Imaging into Clinical Use

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Breakthrough discovery could help young girls suffering from rare form of epilepsy

Breakthrough discovery could help young girls suffering from rare form of epilepsy

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

New article highlights learnings gleaned from monitoring complex HIV clinical trials in Africa

New article highlights learnings gleaned from monitoring complex HIV clinical trials in Africa

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.